

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.:  
L74899DL1993PLC056594

Ref: STEX/OUTCOME/2021-22

Date: 13.08.2021

**BSE Limited**

Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**Company No.: 531146**

**Sub. : Outcome of Board Meeting**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2021.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2021 as **Annexure-A** and
- Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Approved draft Annual Report for the financial year 2020-21.
- The 28<sup>th</sup> AGM of the Company will be held on Saturday, September 25, 2021 at 11.00 AM at ISKCON Auditorium, Hare Krishna Hill, Sant Nagar Main Road, East of Kailash, New Delhi-110065.
- Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Saturday, September 18, 2021 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialised form) to cast their vote electronically from Wednesday, September 22, 2021 to Friday, September 24, 2021.
- In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Rs. 1 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2020-21. The aforesaid register will remain close from Sunday, September 19, 2021 to Saturday, September 25, 2021 (both days inclusive)

The meeting of the Board of Directors commenced 2.00 p.m. and concluded at 4.00 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2021, as approved by the Board, will also be available on the Company's website www.medicamen.com

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited

  
Parul Choudhary  
Company Secretary  
ACS44157



Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.:  
L74899DL1993PLC056594

## KEY HIGHLIGHTS


### *Medicamen Biotech Limited posts strong Results with a steady revenue growth*

Revenue Grows for Q1FY21 grows by 5.38% YoY

EBITDA for Q1FY21 grows by 53.58% YoY

PAT for Q1FY21 grows by 97.22% YoY

- Medicamen Biotech Ltd (MBL), has successfully launched multiple pharma products in more than 30 countries. MBL has invested substantially in R&D and manufacturing of APIs & dosage forms for oncology products with a vision to be a global leader in oncology generics by offering cost effective products with best-in-class quality.
- MBL has firm plans & investments for global roll out of its oncology products, including in USA, Europe, Latin America, Asia Pacific, MENA, etc through a combination of own team and alliance partners.
- The Company is now focusing on Oncology therapeutics. The formulation plant at Unit-II Haridwar is under validations. The formulations of the products which are to be launched in regulated and emerging market have been finalised.
- A team of highly experienced people headed by Mr. Subir Chopra having more than 25 years of experience in various companies including Alkem Laboratories Ltd. And Shilpa Medicare Limited in domestic oncology joined for marketing oncology products in Domestic market. The portfolio for regulated market is under active discussion.
- Apart from the above, a set of 10 non-oncology formulations is also being determined in R&D for EU market filings.




Works: SP-1192, A & B Phase-IV, Industrial Area, Distt. Alwar, Bhiwadi - 301019 (Rajasthan),

Works: Unit-I : Plot No.: 86 & 87, Sector-6A, Unit-II : Plot No. : 84 & 85, Sector-6A, IIE, SIDCUL, BHEL, Ranipur, Haridwar - 249403, (Uttarakhand)

## CAPEX HIGHLIGHTS

- ✓ *The Pharma Oncology formulation plant at Haridwar which has commence its operations in the months of March 2021, major revenue/income from oncology plant will come after US FDA approval. However oncology plant will start generating income from domestic operations and to exports to ROW markets after validations are completed.*
- ✓ *As per the guidelines MBL is eligible to be listed on National Stock Exchange now, therefore we are planning to get listed on NSE in current fiscal year.*





## MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : [cs@medicamen.com](mailto:cs@medicamen.com), [www.medicamen.com](http://www.medicamen.com)


Un-audited Standalone and Consolidated Financial Results for the quarter ended on 30th June' 2021

PART I		Rupees in Lacs (Except per Share Data)							
		Standalone				Consolidated			
Particulars	Quarter Ended			Year Ended	Quarter Ended			31.03.2021	
	3 Months Ended 30.06.2021	Preceding 3 Months Ended 31.03.2021	Corresponding 3 Months Ended 30.06.2020	31.03.2021	3 Months Ended 30.06.2021	Preceding 3 Months Ended 31.03.2021	Corresponding 3 Months Ended 30.06.2020	31.03.2021	
	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	
<b>1</b>	<b>Income from operations</b>								
	(a) Net Sales / Income from operations	2,753.03	2,033.74	2,611.52	11,014.65	2,753.03	2,123.88	2,778.35	11,271.61
	(b) Other Income	7.87	53.72	8.41	75.40	7.87	53.72	8.41	75.40
	(c) Total Revenue	<b>2,760.90</b>	<b>2,087.46</b>	<b>2,619.93</b>	<b>11,090.06</b>	<b>2,760.90</b>	<b>2,177.60</b>	<b>2,786.76</b>	<b>11,347.01</b>
<b>2</b>	<b>Expenses</b>								
	a) Cost of Material Consumed	1,224.52	972.81	1,657.04	6,583.62	1,224.52	1,090.08	1,798.17	6,842.01
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	3.39	(118.27)	38.10	104.06	3.39	(118.27)	38.10	104.06
	d) Employees Benefits Expenses	292.46	215.53	216.21	879.17	292.46	233.08	219.93	900.43
	e) Finance Cost	4.41	36.02	23.95	106.40	4.41	36.02	23.95	106.40
	f) Depreciation and Amortisation Expenses	132.97	41.46	69.24	251.97	132.97	41.46	69.24	251.97
	g) Other expenses	628.57	475.58	310.11	1,489.72	628.57	485.17	313.54	1,502.74
	<b>Total Expenses</b>	<b>2,286.33</b>	<b>1,623.12</b>	<b>2,314.66</b>	<b>9,414.94</b>	<b>2,286.33</b>	<b>1,767.54</b>	<b>2,462.94</b>	<b>9,707.61</b>
<b>3</b>	<b>Profit/(Loss) before Exceptional Items &amp; Tax (1 - 2)</b>	<b>474.57</b>	<b>464.35</b>	<b>305.27</b>	<b>1,675.12</b>	<b>474.57</b>	<b>410.07</b>	<b>323.82</b>	<b>1,639.40</b>
<b>4</b>	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) before Extra Ordinary Items &amp; Tax (3 - 4)</b>	<b>474.57</b>	<b>464.35</b>	<b>305.27</b>	<b>1,675.12</b>	<b>474.57</b>	<b>410.07</b>	<b>323.82</b>	<b>1,639.40</b>
<b>6</b>	<b>Tax Expenses</b>								
	Current Year	66.03	45.00	92.30	414.52	66.03	40.36	96.94	414.52
	MAT Credit Entitlement	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(6.59)	5.01	2.48	11.94	(6.59)	5.01	2.48	11.94
	<b>Total Tax Expense</b>	<b>59.44</b>	<b>50.01</b>	<b>94.78</b>	<b>426.46</b>	<b>59.44</b>	<b>45.38</b>	<b>99.41</b>	<b>426.46</b>
<b>7</b>	<b>Net Profit /Loss for the period from Continuing operation (5- 6)</b>	<b>415.13</b>	<b>414.34</b>	<b>210.49</b>	<b>1,248.66</b>	<b>415.13</b>	<b>364.69</b>	<b>224.41</b>	<b>1,212.94</b>
<b>8</b>	<b>Other Comprehensive Income</b>								
	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-
<b>9</b>	<b>Total Comprehensive Income net of Tax</b>	<b>415.13</b>	<b>414.34</b>	<b>210.49</b>	<b>1,248.66</b>	<b>415.13</b>	<b>364.69</b>	<b>224.41</b>	<b>1,212.94</b>
<b>10</b>	<b>Paid up equity share capital (Rs. 10/- per share)</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>	<b>1,221.66</b>
<b>11</b>	<b>Earning Per Share (Rs.)</b>								
	Basic	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93
	Diluted	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93

### NOTES :

- 1 The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2021.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- 5 During the quarter under review, beta lactum block was shut down for 5-6 weeks for upgradation.
- 6 The Pharma Oncology formulation plant at Haridwar which has commence its operations in the month of March 2021, major revenue/ income from oncology plant will come after US FDA approval. However oncology plant will start generating income from domestic operations and exports to ROW markets after validations are completed.
- 7 Audit report has been carried out by the Statutory Auditors for the above period.
- 8 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors  
Medicamen Biotech Limited

  
 (Rahul Bishnoi)  
 Chairman

Place : New Delhi  
Dated : 13.08.2021

**RAI QIMAT & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**



**INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED  
 QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE  
 REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE  
 REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To

The Board of Directors,  
**Medicamen Biotech Ltd.**  
 1506, Chiranjiv Tower, 43,  
 Nehru Place New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and three months ended June 30, 2021 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
 Chartered Accountants



(Membership Number: 013152C)  
 UDIN: 21080857AAAAE16975

Place: Gurugram  
 Date: 13.08.2021



**INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED  
QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE  
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE  
REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To

**The Board of Directors,  
Medicamen Biotech Limited  
1506, Chiranjiv Tower 43,  
Nehru Place, New Delhi- 110019**


1. We have reviewed the Unaudited Consolidated Financial Results of Medicamen Biotech Limited (the "Parent Company"), and the Subsidiary Company for the quarter and three months ended on June 30, 2021 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2021 (the "Statement")'. The Statement is being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd ( the "Subsidiary" Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to

**RAI QIMAT & ASSOCIATES**  
CHARTERED ACCOUNTANTS



be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
Chartered Accountants



(Membership Number: 013152C)  
UDIN: 21080857AAAAEI5975

Place: Gurugram  
Date: 13.08.2021